312 related articles for article (PubMed ID: 9676180)
21. Vascular disease in scleroderma. Endothelial T lymphocyte-fibroblast interactions.
Kahaleh MB
Rheum Dis Clin North Am; 1990 Feb; 16(1):53-73. PubMed ID: 2406811
[TBL] [Abstract][Full Text] [Related]
22. Unilateral limited scleroderma-like changes following formation of an arteriovenous fistula.
Roberts H; Curnow PA
Australas J Dermatol; 2007 Feb; 48(1):37-9. PubMed ID: 17222301
[TBL] [Abstract][Full Text] [Related]
23. Asymptomatic primary biliary cirrhosis associated with Raynaud's phenomenon, sclerodactyly and teleangiectasia.
Diederichsen H; Clausen C; Lundborg CJ
Dan Med Bull; 1981 Oct; 28(5):212-5. PubMed ID: 7327009
[No Abstract] [Full Text] [Related]
24. [Systemic sclerosis (scleroderma): etiology and pathogenesis--where are we today?].
Stoll T; Brühlmann P; Fontana A; Gmür J; Michel BA
Schweiz Med Wochenschr; 1994 Feb; 124(5):193-203. PubMed ID: 8128201
[TBL] [Abstract][Full Text] [Related]
25. Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study.
Kazandjian S; Fiessinger JN; Camilleri JP; Dadoune JP; Housset E
Acta Derm Venereol; 1982; 62(5):425-9. PubMed ID: 6183893
[TBL] [Abstract][Full Text] [Related]
26. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I
Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
[TBL] [Abstract][Full Text] [Related]
27. [Myositis disclosing systemic scleroderma].
Leys D; Hatron PY; Parent M; Pasquier F; Krivosic I; Petit H
Rev Neurol (Paris); 1984; 140(11):670-2. PubMed ID: 6505497
[TBL] [Abstract][Full Text] [Related]
28. Scleroderma with type III glomerulonephritis and MPO-ANCA antibodies in the serum.
Herrera-Esparza R; Aguilar JL; Saucedo A; González I; López-Robles E; Avalos-Díaz E
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):617-20. PubMed ID: 16164722
[TBL] [Abstract][Full Text] [Related]
29. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
30. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy.
Freemont AJ; Hoyland J; Fielding P; Hodson N; Jayson MI
Br J Dermatol; 1992 Jun; 126(6):561-8. PubMed ID: 1610706
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis of Raynaud's phenomenon.
Herrick AL
Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
[TBL] [Abstract][Full Text] [Related]
32. Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis.
Cracowski JL; Kom GD; Salvat-Melis M; Renversez JC; McCord G; Boignard A; Carpentier PH; Schwedhelm E
Free Radic Biol Med; 2006 May; 40(10):1732-7. PubMed ID: 16678012
[TBL] [Abstract][Full Text] [Related]
33. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma.
Akesson A; Wollheim FA
Br J Rheumatol; 1989 Aug; 28(4):281-6. PubMed ID: 2787182
[TBL] [Abstract][Full Text] [Related]
34. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
35. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Henness S; Wigley FM
Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
[TBL] [Abstract][Full Text] [Related]
36. Scleroderma (progressive systemic sclerosis, PSS); pathophysiological, clinical and pharmacological aspects of the syndrome.
Herbai G
Acta Med Acad Sci Hung; 1978; 35(3-4):201-11. PubMed ID: 756110
[TBL] [Abstract][Full Text] [Related]
37. [Raynaud's phenomena: diagnostic and treatment study].
Priollet P
Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and management of scleroderma peripheral vascular disease.
Herrick A
Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
[TBL] [Abstract][Full Text] [Related]
39. Raynaud phenomenon and the vascular disease in scleroderma.
Kahaleh MB
Curr Opin Rheumatol; 2004 Nov; 16(6):718-22. PubMed ID: 15577610
[TBL] [Abstract][Full Text] [Related]
40. [Sclerodermic acrosyndromes].
Carpentier PH
Rev Prat; 2002 Nov; 52(17):1891-5. PubMed ID: 12532865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
